TrinityBridge Ltd Purchases Shares of 3,474 Merck & Co., Inc. $MRK

TrinityBridge Ltd purchased a new position in Merck & Co., Inc. (NYSE:MRK) in the 2nd quarter, Holdings Channel.com reports. The firm purchased 3,474 shares of the company’s stock, valued at approximately $446,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Kingdom Financial Group LLC. bought a new position in Merck & Co., Inc. during the 4th quarter valued at about $25,000. Abound Financial LLC acquired a new position in Merck & Co., Inc. during the 4th quarter worth $26,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. in the 4th quarter valued at $26,000. High Note Wealth LLC increased its stake in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. acquired a new position in Merck & Co., Inc. during the 4th quarter valued at about $31,000. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive melanoma results strengthen the pipeline. Merck and Moderna reported positive Phase 3 topline results for intismeran autogene, an individualized neoantigen therapy used with KEYTRUDA in resected melanoma. The program could create a new growth opportunity and help extend KEYTRUDA’s commercial runway. Merck Surges on a Melanoma Win
• Positive Sentiment: A busy fall catalyst calendar is attracting investors. Upcoming FDA decisions, additional pipeline updates and a pivotal cancer-vaccine readout could materially influence expectations for Merck’s post-KEYTRUDA growth profile. What Would It Take to Get MRK Stock to $200?
• Positive Sentiment: Pipeline progress, new product launches and potential M&A are improving the long-term growth outlook and easing concerns about eventual KEYTRUDA revenue pressure. Merck Stock Hits New 52-Week High
• Positive Sentiment: Analysts have become more bullish. Wolfe Research raised its price target from $155 to $180 with an outperform rating, while Argus increased its target from $145 to $170 and upgraded the stock to buy. These revisions provide additional support for the recent advance.
• Neutral Sentiment: The cancer-vaccine opportunity remains uncertain. Reuters noted that evidence for broad use of the personalized therapy is still limited, with manufacturing, patient-selection and clinical-adoption challenges potentially affecting its commercial impact. How the Merck-Moderna Cancer Vaccine Works
• Negative Sentiment: Valuation and execution risks are increasing. After gaining roughly 19% over the past month and trading near its 52-week high, MRK is approaching analyst targets, leaving less room for disappointment. Investors will likely focus on whether upcoming approvals and trial results can justify further upside.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Chirfi Guindo sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president owned 36,613 shares in the company, valued at $4,942,755. The trade was a 21.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 228,238 shares of company stock valued at $29,977,783 over the last ninety days. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $153.21 on Thursday. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $156.92. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The firm’s 50-day simple moving average is $130.39 and its 200 day simple moving average is $122.04. The firm has a market cap of $378.00 billion, a price-to-earnings ratio of 122.57, a P/E/G ratio of 6.56 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the previous year, the firm posted $2.13 EPS. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on MRK shares. Jefferies Financial Group downgraded Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Argus increased their price objective on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. Citigroup began coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective for the company. Finally, Bank of America increased their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $147.60.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.